DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Nonsmall Cell Lung Cancer

First Posted Date: 2021-02-05

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04741789

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2021-02-03

Last Posted Date: 2023-05-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 268

Registration Number: NCT04735354

Locations: 🇮🇳
Novartis Investigational Site, Mumbai, India

A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Phase 3

Terminated

Conditions: Thyroid Eye Disease
Graves Orbitopathy

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2021-02-03

Last Posted Date: 2025-01-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT04737330

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

Phase 3

Completed

Conditions: Non-radiographic Axial Spondyloarthritis

Interventions: Drug: Secukinumab
Drug: Placebo

First Posted Date: 2021-02-01

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 138

Registration Number: NCT04732117

Locations: 🇨🇳
Novartis Investigative Site, Zhejiang, China

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Alpelisib
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: Olaparib

First Posted Date: 2021-01-28

Last Posted Date: 2025-02-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 358

Registration Number: NCT04729387

Locations: 🇺🇸
Arizona Oncology Associates, Phoenix, Arizona, United States
🇺🇸
HonorHealth, Phoenix, Arizona, United States
🇺🇸
Texas Oncology Northeast Texas, Tyler, Texas, United States

and more 12 locations

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Phase 2

Terminated

Conditions: Major Depressive Disorder With Suicidal Ideation With Intent

Interventions: Drug: MIJ821 Intravenous Injection
Drug: Placebo Intravenous Injection

First Posted Date: 2021-01-25

Last Posted Date: 2024-04-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT04722666

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: 68Ga-PSMA-11
Drug: 177Lu-PSMA-617
Drug: ARDT
Drug: ADT

First Posted Date: 2021-01-22

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1144

Registration Number: NCT04720157

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Mississippi Med Ctr, Jackson, Mississippi, United States
🇺🇸
St. Louis University, Saint Louis, Missouri, United States

and more 65 locations

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Phase 3

Completed

Conditions: Adult Onset Still's Disease

Interventions: Biological: Canakinumab

First Posted Date: 2021-01-22

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT04717635

Locations: 🇯🇵
Novartis Investigative Site, Chiba, Japan

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Early Phase 1

Terminated

Conditions: Pancreatic Ductal Adenocarcinoma
Brain Neoplasms
Glioblastoma Multiforme
Gastroesophageal Adenocarcinoma

Interventions: Drug: 68Ga-FF58

First Posted Date: 2021-01-15

Last Posted Date: 2025-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT04712721

Locations: 🇩🇪
Novartis Investigative Site, Essen, Germany

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Other: Secukinumab Placebo
Drug: AIN457

First Posted Date: 2021-01-15

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04711902

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy